

10/771,696

-27-

PC9985B

REMARKS

Restriction to one of the following inventions was required under 35 U.S.C § 121:

- I. Claims 13-27, drawn to a method of using the products of Formula (I) wherein on of Y^1 , Y^2 , Y^3 and Y^4 is N and the remaining are either CH or C(L), classified in class 514, subclass 299+.
- II. Claims 13-23 and 25-27, drawn to a method of using the products of Formula (1) wherein Y^1 , Y^2 , Y^3 and Y^4 are each CH or C(L), classified in class 514, subclass 386+.
- III. Claims 13-19 and 25-27, drawn to a method of using the products of Formula (I) not embraced by Groups I or II, classified in class 514, subclass 241+.

Applicants provisionally elect Group I, claims 13-27, for prosecution purposes, with traverse.

Applicants traverse the restriction requirement based on the following grounds. It is respectfully submitted that the restriction requirement practice was established to promote efficiency of prosecution in the patent office. The groups of claims relate to a common generic core and are all classified in the same class, 514. Since there is a great amount of cross-classification amongst the sub-classes in this class, it is respectfully submitted the examination of the claims in a single application would be efficient, thereby prompting the grounds for the establishment of the restriction requirement practice. Hence, it is respectfully submitted that the restriction should not be required and that applicants have traversed the restriction requirement. However, as stated above, applicants have elected the claims of Group I pending reconsideration of the restriction requirement.

Further, applicants are required under 35 U.S.C. § 121 to elect a single disclosed species. For the purpose of prosecution, applicants elect the species set forth in Claim 24 of the present application the elected compound is 2-ethyl-4,6-dimethyl-1-(4-{2-[(4-methoxyphenyl)sulfonyl]amino} carboxyl)amino] ethyl}phenyl)-1H-imidazo[4,5-C]pyridine.

10/771,696


-28-

PC9985B

Further, applicants were required to elect a single method of use from the methods of use listed on pages 4-5 of the instant specification. Applicants hereby provisionally elect a method of treating pain for the purposes of prosecution.

The application is now in condition for allowance, which allowance is respectfully solicited.

Respectfully submitted,

Dated: 10/13/04

David R. Kurlandsky
Registration No. 41,505
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-7304
Facsimile: (734) 622-2928